The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

INTRODUCTION: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years comp...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Lymphat Cancer
Autores principales: Ujjani, Chaitra, Mato, Anthony, Hill, Brian T, Allan, John N, Lansigan, Frederick, Jacobs, Ryan, Skarbnik, Alan, Tuncer, Hande, Pagel, John, Brander, Danielle, Cheson, Bruce, Barr, Paul, Roeker, Lindsey E, Pu, Jeffrey, Shah, Nirav N, Goy, Andre, Schuster, Stephen J, Lamanna, Nicole, Sehgal, Alison, Tam, Constantine S, Shadman, Mazyar
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7473982/
https://ncbi.nlm.nih.gov/pubmed/32943973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S262592
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares